Skip to content
naulon
Not checkedNot checked for notices yet.

Review: Neutralizing antibodies against interferon-beta

Per Soelberg Sorensen

Therapeutic Advances in Neurological Disorders · 2008

doi:10.1177/1756285608095144 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

The development of neutralizing antibodies (NAbs) is a major problem in multiple sclerosis (MS) patients treated with interferon-beta (IFN-β). Whereas binding antibodies (BAbs) can be demonstrated in the vast majority of patients, only a smaller proportion of patients develop NAbs. The principle in NAb in vitro assays is the utilization of cultured cell lines that are responsive to IFN-β. The cytopathic effect (CPE) assay measures the capacity of NAbs to neutralize IFN-β's protective effect on cells challenged with virus and the MxA induction assay measures the ability of NAbs to reduce the IFN-β-induced expression of MxA, either at the mRNA or the protein level. A titer of ≥20 neutralizing units/ml traditionally defines NAb positivity. NAbs in high titers completely abrogate the in vivo response to IFN-β, whereas the effect of low and intermediate titers is unpredictable. As clinically important NAbs appear only after 9—18 months IFN-β therapy, short-term studies of two years or less are unsuitable for evaluation of clinical NAb effects. All long-term trials of three years or more concordantly show evidence of a detrimental effect of NAbs on relapses, disease activity on MRI, or on disease progression. Persistent high titers of NAbs indicate an abrogation of the biological response and, hence, absence of therapeutic efficacy, and this observation should lead to a change of therapy. As low and medium titers are ambiguous treatment decisions in patients with low NAb titres should be guided by determination of in vivo mRNA MxA induction and clinical disease activity.

Abstract licence: CC BY-NC

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.